Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France

被引：0

作者：

Perol, M. ^{[1
]}

Filleron, T. ^{[2
]}

Quantin, X. ^{[3
]}

Chouaid, C. ^{[4
]}

Valette, C. Audigier ^{[5
]}

Lena, H. ^{[6
]}

Kaderbhai, C. ^{[7
]}

Fabre, C. ^{[8
]}

Santorelli, M. ^{[9
]}

Bensimon, L. ^{[10
]}

Burke, T. ^{[11
]}

Couch, D. ^{[12
]}

Nguyen, E. ^{[12
]}

Courtinard, C. ^{[12
]}

机构：

[1] Ctr Leon Berard, Dept Med Oncol, Lyon, France

[2] Ctr Claudius Regaud, Biostat, Toulouse, France

[3] ICM Reg Canc Inst Montpellier, Montpellier, France

[4] CH Intercommunal Creteil, Creteil, France

[5] Hop St Musse, Toulon, France

[6] CHU Pontchaillou, Rennes, France

[7] Ctr Georges Francois Leclerc, Dijon, France

[8] IQVIA Co France, Capionis, Courbevoie, France

[9] Merck & Co Inc, Rahway, NJ USA

[10] MSD France, Dir Ass Evaluat Med Econ & Epidemiol, Puteaux La Defense, France

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] UNICANCER, Data Off, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

109P

引用

页码：S757 / S758

页数：2

共 50 条

[21] Real-world comparative effectiveness and safety of pembrolizumab for PD-L1≥50% metastatic non-small-cell lung cancer [J].

Parmar, Ambica ;

Lu, Brandon ;

Luo, Jin ;

Chan, Kelvin K. .

FUTURE ONCOLOGY, 2024, 20 (36) :2879-2888

[22] Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest [J].

Mountzios, G. ;

Signorelli, D. ;

Cobo, J. Rey ;

Banini, M. ;

Economopoulou, P. ;

Lo Russo, G. ;

Baxevanos, P. T. ;

Roila, F. ;

de Toma, A. ;

Banna, G. ;

Christopoulou, A. ;

Jimenez, B. ;

Linardou, H. ;

Calles, A. ;

Galetta, D. ;

Addeo, A. ;

Camerini, A. ;

Kosmidis, P. A. ;

Garassino, M. C. ;

Metro, G. .

ANNALS OF ONCOLOGY, 2019, 30

[23] Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting [J].

Gadgeel, Shirish M. ;

Rai, Pragya ;

Annavarapu, Srinivas ;

Alam, Sartaj ;

Goldschmidt, Jerome H. ;

West, Howard ;

Santorelli, Melissa ;

Martins, Renata Eiras .

FRONTIERS IN ONCOLOGY, 2024, 14

[24] Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data [J].

Velcheti, Vamsidhar ;

Hu, Xiaohan ;

Li, Yeran ;

El-Osta, Hazem ;

Pietanza, M. Catherine ;

Burke, Thomas .

CANCERS, 2022, 14 (04)

[25] Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data [J].

Dudnik, Elizabeth ;

Moskovitz, Mor ;

Rottenberg, Yakir ;

Lobachov, Anastasiya ;

Mandelboim, Rinat ;

Shochat, Tzippy ;

Urban, Damien ;

Wollner, Mira ;

Nechushtan, Hovav ;

Rotem, Ofer ;

Zer, Alona ;

Daher, Sameh ;

Bar, Jair .

ONCOIMMUNOLOGY, 2021, 10 (01)

[26] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50% [J].

Liu, Qiao ;

Zhou, Zhen ;

Luo, Xia ;

Yi, Lidan ;

Peng, Liubao ;

Wan, Xiaomin ;

Tan, Chongqing ;

Zeng, Xiaohui .

FRONTIERS IN PHARMACOLOGY, 2022, 12

[27] PD-L1 TPS ANALYSIS IN REAL-WORLD CLINICAL PRACTICE: EVALUATION OF SPECIMENS OBTAINED BY RESPIRATORY ENDOSCOPIC BIOPSY [J].

Tanaka, Midori ;

Horinouchi, Hidehito ;

Matsumoto, Yuji ;

Nakai, Toshiyuki ;

Tsuchida, Takaaki ;

Murakami, Shuji ;

Goto, Yasushi ;

Kanda, Shintaro ;

Fujiwara, Yutaka ;

Yamamoto, Noboru ;

Motoi, Noriko ;

Ohe, Yuichiro .

RESPIROLOGY, 2017, 22 :74-74

[28] Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes [J].

Cortellini, Alessio ;

Friedlaender, Alex ;

Banna, Giuseppe L. ;

Porzio, Giampiero ;

Bersanelli, Melissa ;

Cappuzzo, Federico ;

Aerts, Joachim G. J., V ;

Giusti, Raffaele ;

Bria, Emilio ;

Cortinovis, Diego ;

Grossi, Francesco ;

Migliorino, Maria R. ;

Galetta, Domenico ;

Passiglia, Francesco ;

Berardi, Rossana ;

Mazzoni, Francesca ;

Di Noia, Vincenzo ;

Signorelli, Diego ;

Tuzi, Alessandro ;

Gelibter, Alain ;

Marchetti, Paolo ;

Macerelli, Marianna ;

Rastelli, Francesca ;

Chiari, Rita ;

Rocco, Danilo ;

Inno, Alessandro ;

Di Marino, Pietro ;

Mansueto, Giovanni ;

Zoratto, Federica ;

Santoni, Matteo ;

Tudini, Marianna ;

Ghidini, Michele ;

Filetti, Marco ;

Catino, Annamaria ;

Pizzutilo, Pamela ;

Sala, Luca ;

Occhipinti, Mario Alberto ;

Citarella, Fabrizio ;

Marco, Russano ;

Torniai, Mariangela ;

Cantini, Luca ;

Follador, Alessandro ;

Sforza, Vincenzo ;

Nigro, Olga ;

Ferrara, Miriam G. ;

D'Argento, Ettore ;

Leonetti, Alessandro ;

Pettoruti, Linda ;

Antonuzzo, Lorenzo ;

Scodes, Simona .

CLINICAL LUNG CANCER, 2020, 21 (06) :498-+

[29] Immunotherapy for PDL1-high (TPS≥50%) metastatic NSCLC: Results in real-world oncology practice [J].

Srdic, D. ;

Bitar, L. ;

Seiwerth, F. ;

Gabaj, N. Nikolac ;

Marusic, A. ;

Vuletic, L. Batelja ;

Badovinac, S. ;

Plestina, S. ;

Samarzija, M. ;

Jakopovic, M. .

ANNALS OF ONCOLOGY, 2021, 32 :S1015-S1015

[30] Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study [J].

Lin, D. ;

Yang, X. ;

Jiang, L. ;

Wang, W. ;

Hou, Y. ;

Li, Y. ;

Jin, Y. ;

Fan, X. ;

Sun, W. ;

Yun, J. ;

Li, P. ;

Kuang, D. ;

Zhang, L. ;

Ni, J. ;

Mao, A. ;

Tang, W. ;

Liu, Z. ;

Wang, J. ;

Xiao, S. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :S410-S410

← 1 2 3 4 5 →

Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS&gt;50%) metastatic NSCLC in France

Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France